What is Prota Therapeutics?
Prota Therapeutics operates as a late clinical-stage biotechnology enterprise dedicated to the development of transformative allergen oral immunotherapies. The company is primarily focused on mitigating the impact of food allergies, with a specialized emphasis on peanut allergy treatments. By leveraging more than twenty years of foundational research spearheaded by Professor Mimi Tang at the Murdoch Childrens Research Institute, Prota has successfully transitioned its lead candidate, PRT120, into a phase-3 ready status. This clinical milestone positions the organization at the forefront of medical innovation, aiming to provide long-term therapeutic solutions that significantly enhance the quality of life for patients suffering from life-threatening allergic conditions.
How much funding has Prota Therapeutics raised?
Prota Therapeutics has raised a total of $21M across 1 funding round:
Other Financing Round
$21M
Other Financing Round (2024): $21M, investors not publicly disclosed
Key Investors in Prota Therapeutics
Undisclosed Investor
An undisclosed institutional partner providing strategic capital to support late-stage clinical development and operational scaling.
Undisclosed Investor
A private investment entity focused on high-impact biotechnology ventures and long-term medical research initiatives.
Undisclosed Investor
A strategic backer specializing in the advancement of novel therapeutic platforms within the immunology and allergy treatment sectors.
What's next for Prota Therapeutics?
The recent infusion of capital is strategically earmarked to accelerate the phase-3 clinical development of PRT120. As the company moves toward potential regulatory milestones, the focus will shift from research-heavy operations to large-scale clinical execution and commercial readiness planning. Prota Therapeutics is well-positioned to navigate the complex landscape of allergen immunotherapy, leveraging its robust intellectual property and clinical data to potentially redefine the standard of care for food allergy management. Future growth will likely involve scaling manufacturing capabilities and preparing for global market entry, contingent upon successful trial outcomes and subsequent regulatory approvals.
See full Prota Therapeutics company page
